References
- Richardson MD. Changing patterns and trends in systemic fungal infections. J Antimicrob Chemother 2005;56:i5–i11
- Fukuda T, Boeckh M, Carter RA, et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 2003;102:827–33
- Caggiano V, Weiss RV, Rickert TS, et al. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 2005;103:1916–24
- Jansen JP, Meis JF, Blijlevens NM, et al. Economic evaluation of voriconazole in the treatment of invasive aspergillosis in the Netherlands. Curr Med Res Opin 2005;21:1535–46
- Maertens J, Marchetti O, Herbrecht R, et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 update. Bone Marrow Transplant 2011;46:709–18.
- Keating GM. Posaconazole. Drugs 2005;65:1553–67
- Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356:348–59
- Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007;356:335–47
- Papadopoulos G, Hunt S, Prasad M. Adapting a global cost-effectiveness model to local country requirements: posaconazole case study. J Med Econ 2013;16:374–80
- Stam WB, O'Sullivan AK, Rijnders B, et al. Economic evaluation of posaconazole versus standard azole prophylaxis in high risk neutropenic patients in the Netherlands. Eur J Haematol 2008;81:467–74
- Collins CD, Ellis JJ, Kaul DR. Comparative cost-effectiveness of posaconazole versus fluconazole or itraconazole prophylaxis in patients with prolonged neutropenia. Am J Health Syst Pharm 2008;65:2237–43
- De la Camara R, Jarque I, Sanz MA, et al. Economic evaluation of posaconazole vs fluconazole in the prevention of invasive fungal infections in patients with GVHD following haematopoietic SCT. Bone Marrow Transplant 2010;45:925–32
- Michallet M, Gangneux JP, Lafuma A, et al. Cost effectiveness of posaconazole in the prophylaxis of invasive fungal infections in acute leukaemia patients for the French healthcare system. J Med Econ 2011;14:28–35
- Lyseng-Williamson KA. Posaconazole: a pharmacoeconomic review of its use in the prophylaxis of invasive fungal disease in immunocompromised hosts. PharmacoEconomics 2011;29:251–68
- Sanchez-Ortega I, Patino B, Arnan M, et al. Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole vs itraconazole in allogeneic blood and marrow transplantation. Bone Marrow Transplant 2011;46:733–9
- Drummond MF, O’Brien B, Stoddart GL, et al. Methods for the Economic Evaluation of Health Care Programmes, 2nd edn. New York, NY: Oxford University Press, 1997
- Spanish General Council of Pharmacists (Consejo General de Colegios Oficiales de Farmaceuticos). Database of medicines. https://botplusweb.portalfarma.com/botplus.asp. Accessed July 27, 2011
- Spanish Health Costs (CD-ROM database). Barcelona: Centre d’Estudis en Economia de la Salut de la Politica Socia, 2005. SOIKOS version 2.2
- Campbell MK, Torgerson DJ. Bootstrapping: estimating confidence intervals for cost-effectiveness ratios. QJM 1999;92:177–82
- De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008;46:1813–21
- National Cancer Institute. Common terminology criteria for adverse events (CTCAE), v3.0. 2006. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_30. Accessed
- Menzin J, Meyers JL, Friedman M, et al. Mortality, length of hospitalization, and costs associated with invasive fungal infections in high-risk patients. Am J Health Syst Pharm 2009;66:1711–7
- van Gool R. The cost of treating systemic fungal infections. Drugs 2001;61:49–56
- Worldwide inflation data. http://www.inflation.eu/inflation-rates/spain/historic-inflation. Accessed March 7, 2013